Literature DB >> 33497575

Building a Chemical Toolbox for Human Pregnane X Receptor Research: Discovery of Agonists, Inverse Agonists, and Antagonists Among Analogs Based on the Unique Chemical Scaffold of SPA70.

Yongtao Li1, Wenwei Lin1, William C Wright1, Sergio C Chai1, Jing Wu1, Taosheng Chen1.   

Abstract

Pregnane X receptor (PXR) plays roles in detoxification and other physiological processes. PXR activation may enhance drug metabolism (leading to adverse drug reactions) or inhibit inflammation. Therefore, PXR agonists, antagonists, and inverse agonists may serve as research tools and drug candidates. However, a specific PXR modulator with an associated structure-activity relationship is lacking. Based on the scaffold of specific human PXR (hPXR) antagonist SPA70 (10), we developed 81 SPA70 analogs and evaluated their receptor-binding and cellular activities. Interestingly, analogs with subtle structural differences displayed divergent cellular activities, including agonistic, dual inverse agonistic and antagonistic, antagonistic, and partial agonistic/partial antagonistic activities (as in compounds 111, 10, 97, and 42, respectively). We generated a pharmacophore model that represents 81 SPA70 analogs, and docking models that correlate strong interactions between the compounds and residues in the AF-2 helix with agonistic activity. These compounds are novel chemical tools for studying hPXR.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33497575      PMCID: PMC7880548          DOI: 10.1021/acs.jmedchem.0c02201

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  52 in total

1.  Palladium-mediated fluorination of arylboronic acids.

Authors:  Takeru Furuya; Hanns Martin Kaiser; Tobias Ritter
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Long march to approval.

Authors:  E Corcoran
Journal:  Sci Am       Date:  1988-10       Impact factor: 2.142

Review 3.  Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 4.  Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.

Authors:  Tomas Smutny; Sridhar Mani; Petr Pavek
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

Review 5.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

6.  Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome.

Authors:  Zhengdong Zhang; Paula E Burch; Austin J Cooney; Rainer B Lanz; Fred A Pereira; Jiaqian Wu; Richard A Gibbs; George Weinstock; David A Wheeler
Journal:  Genome Res       Date:  2004-04       Impact factor: 9.043

Review 7.  Mechanisms of cytochrome P450 induction.

Authors:  Leslie M Tompkins; Andrew D Wallace
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

8.  Development of BODIPY FL vindoline as a novel and high-affinity pregnane X receptor fluorescent probe.

Authors:  Wenwei Lin; Jiuyu Liu; Cynthia Jeffries; Lei Yang; Yan Lu; Richard E Lee; Taosheng Chen
Journal:  Bioconjug Chem       Date:  2014-08-18       Impact factor: 4.774

9.  SPA70 is a potent antagonist of human pregnane X receptor.

Authors:  Wenwei Lin; Yue-Ming Wang; Sergio C Chai; Lili Lv; Jie Zheng; Jing Wu; Qijun Zhang; Yong-Dong Wang; Patrick R Griffin; Taosheng Chen
Journal:  Nat Commun       Date:  2017-09-29       Impact factor: 14.919

10.  In-silico molecular design of heterocyclic benzimidazole scaffolds as prospective anticancer agents.

Authors:  Sumit Tahlan; Sanjiv Kumar; Kalavathy Ramasamy; Siong Meng Lim; Syed Adnan Ali Shah; Vasudevan Mani; Balasubramanian Narasimhan
Journal:  BMC Chem       Date:  2019-07-11
View more
  6 in total

1.  SJPYT-195: A Designed Nuclear Receptor Degrader That Functions as a Molecular Glue Degrader of GSPT1.

Authors:  Andrew D Huber; Yongtao Li; Wenwei Lin; Annalise N Galbraith; Ashutosh Mishra; Shaina N Porter; Jing Wu; Rebecca R Florke Gee; Wei Zhuang; Shondra M Pruett-Miller; Junmin Peng; Taosheng Chen
Journal:  ACS Med Chem Lett       Date:  2022-07-15       Impact factor: 4.632

2.  Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library.

Authors:  Enni-Kaisa Mustonen; Tatu Pantsar; Azam Rashidian; Juliander Reiner; Matthias Schwab; Stefan Laufer; Oliver Burk
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

3.  A Comparative Study of Human and Zebrafish Pregnane X Receptor Activities of Pesticides and Steroids Using In Vitro Reporter Gene Assays.

Authors:  Nicolas Creusot; Clémentine Garoche; Marina Grimaldi; Abdelhay Boulahtouf; Barbara Chiavarina; William Bourguet; Patrick Balaguer
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

Review 4.  Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance.

Authors:  Xiaxia Niu; Ting Wu; Gege Li; Xinsheng Gu; Yanan Tian; Hongmei Cui
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

5.  Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist.

Authors:  Azam Rashidian; Enni-Kaisa Mustonen; Thales Kronenberger; Matthias Schwab; Oliver Burk; Stefan A Laufer; Tatu Pantsar
Journal:  Comput Struct Biotechnol J       Date:  2022-06-13       Impact factor: 6.155

Review 6.  Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites.

Authors:  Rajamanikkam Kamaraj; Martin Drastik; Jana Maixnerova; Petr Pavek
Journal:  Cells       Date:  2022-09-24       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.